Skip to main content

MICROTECNOLOGIAS DE APLICACION BIOMEDICA EN EL TRATAMIENTO DE LA NEURODEGENERACION EN EL GLAUCOMA

MAT2017-83858-C2-2-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Tunable degrees of neurodegeneration in rats based on microsphere‑induced models of chronic glaucoma, Grados ajustables de neurodegeneración en ratas basados ​​en modelos de glaucoma crónico inducidos por microesferas

  • Bravo Osuna, Irene
  • Aragón Navas, Alba
  • García Herranz, David
  • Herrero Vanrell, María Del Rocío
  • Rodrigo María, Jesús
  • Subias, Manuel
  • Montolío, Alberto
  • Cegoñino, José
  • Martínez-Rincón, Teresa
  • Méndez-Martínez, Silvia
  • Pablo Luis, Emilio
  • Pérez del Palomar, Amaya
  • García-Martín, Elena
This study compares four different animal models of chronic glaucoma against normal aging over 6 months. Chronic glaucoma was induced in 138 Long–Evans rats and compared against 43 agedmatched healthy rats. Twenty‑five rats received episcleral vein sclerosis injections (EPIm cohort) while the rest were injected in the eye anterior chamber with a suspension of biodegradable microspheres: 25 rats received non‑loaded microspheres (N‑L Ms cohort), 45 rats received microspheres loaded with dexamethasone (MsDexa cohort), and 43 rats received microspheres co‑loaded with dexamethasone and fibronectin (MsDexaFibro cohort). Intraocular pressure, neuroretinal function, structure and vitreous interface were evaluated. Each model caused different trends in intraocular pressure, produced specific retinal damage and vitreous signals. The steepest and strongest increase in intraocular pressure was seen in the EPIm cohort and microspheres models were more progressive. The EPIm cohort presented the highest vitreous intensity and percentage loss in the ganglion cell layer, the MsDexa cohort presented the greatest loss in the retinal nerve fiber layer, and the MsDexaFibro cohort presented the greatest loss in total retinal thickness. Function decreased differently among cohorts. Using biodegradable microspheres models it is possible to generate tuned neurodegeneration. These results support the multifactorial nature of glaucoma based on several noxa.
Docta Complutense
Publication Artículo científico (JournalArticle)

Chronic Glaucoma Using Biodegradable Microspheres to Induce Intraocular Pressure Elevation. Six-Month Follow-Up

  • Rodrigo, María Jesús
  • García Herranz, David
  • Subías, Manuel
  • Martínez-Rincón, Teresa
  • Mendez-Martínez, Silvia
  • Bravo Osuna, Irene
  • Carretero, Ana
  • Ruberte, Jesús
  • García Feijoo, Julián
  • Pablo, Luis Emilio
  • Herrero Vanrell, María Del Rocío
  • García-Nartín, Elena
To compare two prolonged animal models of glaucoma over 24 weeks of follow-up. A novel pre-trabecular model of chronic glaucoma was achieved by injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (10–20 μm) (Ms20/10) into the ocular anterior chamber to progressively increase ocular hypertension (OHT). Methods: Rat right eyes were injected to induce OHT: 50% received a suspension of Ms20/10 in the anterior chamber at 0, 2, 4, 8, 12, 16 and 20 weeks, and the other 50% received a sclerosing episcleral vein injection biweekly (EPIm). Ophthalmological clinical signs, intraocular pressure (IOP), neuroretinal functionality measured by electroretinography (ERG), and structural analysis of the retina, retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) protocols using optical coherence tomography (OCT) and histological exams were performed. Results: Both models showed progressive neuroretinal degeneration (p < 0.05), and contralateral eye affectation. The Ms20/10 model showed a more progressive increase in IOP and better preservation of ocular surface. Although no statistical differences were found between models, the EPIm showed a tendency to produce thicker retinal and thinner GCL thicknesses, slower latency and smaller amplitude as measured using ERG, and more aggressive disturbances in retinal histology. In both models, while the GCL showed the greatest percentage loss of thickness, the RNFL showed the greatest and earliest rate of thickness loss. Conclusions: The intracameral model with biodegradable microspheres resulted more like the conditions observed in humans. It was obtained by a less-aggressive mechanism, which allows for adequate study of the pathology over longer periods.
Docta Complutense
Publication Artículo científico (JournalArticle)

Multi‑loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model, Microesferas de PLGA multicargadas como terapia de la neuroretina en un modelo crónico de glaucoma

  • Aragón Navas, Alba
  • Rodrigo, María Jesús
  • Munuera, Inés
  • García Herranz, David
  • Subías, Manuel
  • Villacampa, Pilar
  • García Feijoo, Julián
  • Pablo, Luis
  • García-Martín, Elena
  • Herrero Vanrell, María Del Rocío
  • Bravo Osuna, Irene
This work focused on the co-encapsulation and simultaneous co-delivery of three different neuroprotective drugs in PLGA (poly(lactic-co-glycolic acid) microspheres for the treatment of glaucoma. For formulation optimization, dexamethasone (anti-inflammatory) and ursodeoxycholic acid (anti-apoptotic) were co-loaded by the solid-in-oil-in-water emulsion solvent extraction-evaporation technique as a first step. The incorporation of a water-soluble co-solvent (ethanol) and different amounts of dexamethasone resulted critical for the encapsulation of the neuroprotective agents and their initial release. The optimized formulation was obtained with 60 mg of dexamethasone and using an 80:20 dichloromethane:ethanol ratio. In the second step in the microencapsulation process, the incorporation of the glial cell line-derived neurotrophic factor (GDNF) was performed. The final prototype showed encapsulation efficiencies for each component above 50% with suitable properties for long-term application for at least 3 months. Physicochemical studies were performed by SEM, TEM, DSC, XRD, and gas chromatography. The evaluation of the kinetic release by the Gallagher-Corrigan analysis with Gorrasi correction helped to understand the influence of the co-microencapsulation on the delivery of the different actives from the optimized formulation. The final prototype was tested in a chronic glaucoma animal model. Rats received two intravitreal injections of the neuroprotective treatment within a 24-week follow-up study. The proposed formulation improved retinal ganglion cell (RGC) functionality examined by electroretinography. Also, it was able to maintain a neuroretinal thickness similar to that of healthy animals scanned by in vivo optical coherence tomography, and a higher RGC count on histology compared to glaucomatous animals at the end of the study.
Docta Complutense
Publication Capítulo o parte de un libro (BookPart)

CHAPTER 10: Drug Delivery Systems for the Treatment of Diseases Affecting the Retina and Optic Nerve.

  • Bravo Osuna, Irene
  • Andrés Guerrero, Vanesa
  • Molina Martínez, Irene Teresa
  • Herrero Vanrell, María Del Rocío
Diseases affecting the retina and the optic nerve are the major causes of irreversible blindness in the elderly population. Succesful therapy of these pathologies requires frequent administration of the active molecule close to the retinal target site. Intraocular drug delivery systems (IDDS) are emerging therapeutic tools in the treatment of diseases affecting the posterior segment, as they are able to provide effective concentrations of the drug for a long period, thus avoiding successive injections. Depending on their size, IDDS are classified in implants, microsystems and nanosystems. This chapter covers a general description of the IDDS useful for the treatment of diseases affecting retinal structures. © The Royal Society of Chemistry 2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

  • Rodrigo, María J.
  • Cardiel, María José
  • Fraile, José M.
  • Méndez-Martínez, Silvia
  • Martínez-Rincón, Teresa
  • Subías, Gloria
  • Polo, Víctor
  • Ruberte, J.
  • Ramírez, T.
  • Vispe, Eugenio
  • Luna, C.
  • Mayoral, José A.
  • García-Martín, Elena
Intravitreal administration is widely used in ophthalmological practice to maintain therapeutic drug levels near the neuroretina and because drug delivery systems are necessary to avoid reinjections and sight-threatening side effects. However, currently there is no intravitreal treatment for glaucoma. The brimonidine-LAPONITE® formulation was created with the aim of treating glaucoma for extended periods with a single intravitreal injection. Glaucoma was induced by producing ocular hypertension in two rat cohorts: [BRI-LAP] and [non-bri], with and without treatment, respectively. Eyes treated with brimonidine-LAPONITE® showed lower ocular pressure levels up to week 8 (p < 0.001), functional neuroprotection explored by scotopic and photopic negative response electroretinography (p = 0.042), and structural protection of the retina, retinal nerve fibre layer and ganglion cell layer (p = 0.038), especially on the superior-inferior axis explored by optical coherence tomography, which was corroborated by a higher retinal ganglion cell count (p = 0.040) using immunohistochemistry (Brn3a antibody) up to the end of the study (week 24). Furthermore, delayed neuroprotection was detected in the contralateral eye. Brimonidine was detected in treated rat eyes for up to 6 months. Brimonidine-LAPONITE® seems to be a potential sustained-delivery intravitreal drug for glaucoma treatment., This paper was supported by the Rio Hortega Research Grant M17/00213, PI17/01726, PI17/01946 (Instituto de Salud Carlos III), and by MAT2017-83858-C2-2 MINECO/AEI/ERDF, EU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation

  • Prieto, Esther
  • Cardiel, María José
  • Vispe, Eugenio
  • Idoipe, Miriam
  • García-Martín, Elena
  • Fraile, José M.
  • Polo-Llorens, Vicente
  • Mayoral, José A.
  • Pablo-Júlvez, Luis E.
  • Rodrigo, María J.
This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier—DEX/LAP 1:10 w w−1 formulation; 10 mg ml−1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml−1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1–4–12–24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g−1 d−1) than after IV administration of the DEX solution (317.17 ng g−1 d−1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 ± 311.15 ng g−1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 ± 20.85 ng g−1) and sclera (25.46 ± 44.09 ng g−1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases., This paper was supported by the Carlos III Health Institute (Programme Grant PI12/02285), by Rio Hortega Research Grant M17/00213, PI17/01726, PI17/01946 (Carlos III Health Institute), by MAT2017-83858-C2-2 MINECO/AEI/FEDER, EU, and by the Regional Government of Aragon (E37_17R group, co-financed under FEDER 2014–2020 'Construyendo Europa desde Aragón')., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Monitoring new long-lasting intravitreal formulation for glaucoma with vitreous images using optical coherence tomography

  • Rodrigo, María J.
  • Pérez del Palomar, Amaya
  • Montolío, Alberto
  • Méndez-Martínez, Silvia
  • Subias, Manuel
  • Cardiel, María José
  • Martínez-Rincón, Teresa
  • Cegoñino, José
  • Fraile, José M.
  • Vispe, Eugenio
  • Mayoral, José A.
  • Polo-Llorens, Vicente
  • García-Martín, Elena
This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery., Intravitreal injection is the gold standard therapeutic option for posterior segment pathologies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF., This study was supported by Carlos III Health Institute, (grants numbers: M17/00213, PI17/01726, PI17/01946), and by MINECO/AEI/ERDF, EU (grants numbers: MAT2017-83858-C2-2)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Laponite for biomedical applications: An ophthalmological perspective

  • Rodrigo, María J.
  • Cardiel, María José
  • Fraile, José M.
  • Mayoral, José A.
  • Pablo-Júlvez, Luis E.
  • García-Martín, Elena
Clay minerals have been applied in biomedicine for thousands of years. Laponite is a nanostructured synthetic clay with the capacity to retain and progressively release drugs. In recent years there has been a resurgence of interest in Laponite application in various biomedical areas. This is the first paper to review the potential biomedical applications of Laponite in ophthalmology. The introduction briefly covers the physical, chemical, rheological, and biocompatibility features of different routes of administration. After that, emphasis is placed on 1) drug delivery for antibiotics, anti-inflammatories, growth factors, other proteins, and cancer treatment; 2) bleeding prevention or treatment; and 3) tissue engineering through regenerative medicine using scaffolds in intraocular and extraocular tissue. Although most scientific research is not performed on the eye, both the findings and the new treatments resulting from that research are potentially applicable in ophthalmology since many of the drugs used are the same, the tissue evaluated in vitro or in vivo is also present in the eye, and the pathologies treated also occur in the eye. Finally, future prospects for this emerging field are discussed., This study was supported by Grants M17/00213, JR22/00057, PI17/01726, PI17/01946, and PI20/00437 (Carlos III Health Institute), and by MAT2017-83858-C2-1, MAT2017-83858-C2-2, PID2020-113281 R B-C2-1, and PID2020-113281 R B-C2-2 funded by (MCIN/AEI/10.13039/501 100 011 033)., Peer reviewed
Docta Complutense
Publication Artículo científico (JournalArticle)

Immune Analysis Using Vitreous Optical Coherence Tomography Imaging in Rats with Steroid-Induced Glaucoma

  • Aragón Navas, Alba
  • Bravo Osuna, Irene
  • Herrero Vanrell, María Del Rocío
  • Rodrigo, María Jesús
  • Subías, Manuel
  • Montolío, Alberto
  • Martínez-Rincón, Teresa
  • Pablo, Luis E
  • Cegoñino, Jose
  • García-Martín, Elena
  • Pérez del Palomar, Amaya
Glaucoma is a multifactorial pathology involving the immune system. The subclinical immune response plays a homeostatic role in healthy situations, but in pathological situations, it produces imbalances. Optical coherence tomography detects immune cells in the vitreous as hyperreflective opacities and these are subsequently characterised by computational analysis. This study monitors the changes in immunity in the vitreous in two steroid-induced glaucoma (SIG) animal models created with drug delivery systems (microspheres loaded with dexamethasone and dexamethasone/fibronectin), comparing both sexes and healthy controls over six months. SIG eyes tended to present greater intensity and a higher number of vitreous opacities (p < 0.05), with dynamic fluctuations in the percentage of isolated cells (10 μm2), non-activated cells (10–50 μm2), activated cells (50–250 μm2) and cell complexes (>250 μm2). Both SIG models presented an anti-inflammatory profile, with non-activated cells being the largest population in this study. However, smaller opacities (isolated cells) seemed to be the first responder to noxa since they were the most rounded (recruitment), coinciding with peak intraocular pressure increase, and showed the highest mean Intensity (intracellular machinery), even in the contralateral eye, and a major change in orientation (motility). Studying the features of hyperreflective opacities in the vitreous using OCT could be a useful biomarker of glaucoma.
Docta Complutense
Publication Artículo científico (JournalArticle)

Influence of Chronic Ocular Hypertension on Emmetropia: Refractive, Structural and Functional Study in Two Rat Models

  • Mendez-Martínez, Silvia
  • Martínez-rincón, Teresa
  • Subías, Manuel
  • Pablo, Luis E
  • García Herranz, David
  • García Feijoo, Julián
  • Bravo Osuna, Irene
  • Herrero Vanrell, María Del Rocío
  • García-Martín, Elena
  • Rodrigo, María Jesús
Chronic ocular hypertension (OHT) influences on refraction in youth and causes glaucoma in adulthood. However, the origin of the responsible mechanism is unclear. This study analyzes the effect of mild-moderate chronic OHT on refraction and neuroretina (structure and function) in young-adult Long-Evans rats using optical coherence tomography and electroretinography over 24 weeks. Data from 260 eyes were retrospectively analyzed in two cohorts: an ocular normotension (ONT) cohort (<20 mmHg) and an OHT cohort (>20 mmHg), in which OHT was induced either by sclerosing the episcleral veins (ES group) or by injecting microspheres into the anterior chamber. A trend toward emmetropia was found in both cohorts over time, though it was more pronounced in the OHT cohort (p < 0.001), especially in the ES group (p = 0.001) and males. IOP and refraction were negatively correlated at week 24 (p = 0.010). The OHT cohort showed early thickening in outer retinal sectors (p < 0.050) and the retinal nerve fiber layer, which later thinned. Electroretinography demonstrated early supranormal amplitudes and faster latencies that later declined. Chronic OHT accelerates emmetropia in Long–Evans rat eyes towards slowly progressive myopia, with an initial increase in structure and function that reversed over time.